Catalog No.: PC-20323Not For Human Use, Lab Use Only.
LL-K8-22 is a potent, selective dual degrader of of CDK8 and cyclin C (MDA-MB-468 cell DC50, 2.52 and 2.64 uM), significantly degrades CDK8 without reducing CDK19 and does not degrade other cyclin proteins.
LL-K8-22 is a potent, selective dual degrader of of CDK8 and cyclin C (MDA-MB-468 cell DC50, 2.52 and 2.64 uM), significantly degrades CDK8 without reducing CDK19 and does not degrade other cyclin proteins.
LL-K8-22 showed enhanced anti-proliferative effects over its parental molecule BI-1347.
LL-K8-22 exhibited more pronounced effects on CDK8–cyclin C downstream signaling than BI-1347, suppressing STAT1 phosphorylation more persistently.
LL-K8-22 inhibited E2F- and MYC-driven carcinogenic transcriptional programs.
